Perspectives on managing CML video
Speakers: Andrea Preston/Rebecca Hallam
Andrea Preston is the Divisional Lead Pharmacist for Haematology and Oncology at University Hospital Bristol NHS Foundation Trust. She is also a Cancer Commissioning Pharmacist, providing expert oncology and haematology pharmacy advice to the Specialised Commissioing Team of NHS England, in the South West. Andrea is a subcommitee member of the British Oncology Pharmacy Association Audit and Research Committee and has a special interest in dosing of systemic anticancer therapy in obesity. This interest started during her MSc in Clinical Oncology and her research has been presented at conferences including the British Oncology Pharmacy Association Conference, European Haematology Association conferecnes and the International Conference for Malignant Lymphoma.
Rebecca Hallam is the BMT Advanced Clinical Practitioner also based at the University Hospital Bristol NHS Foundation Trust. During her career, Rebecca has established a nurse-led myeloproliferative disorder clinic, a nurse-led chemotherapy pre-assessment clinic and an e-journal club for nurses on the chemotherapy day unit; she has also implemented the frailty identification tool within haemato-oncology clinics. Rebecca's special interests are in long-term follow-up, late effects of cancer treatment and fraility in haemato-oncology. She holds the position of Secretary of the Haematology Members' Interest Group of UK Oncology Nursing Society.
In this video, Rebecca and Andrea discuss how in their roles of Nurse Specialist and Pharmacist, they support patients during their initial diagnosis of Chronic Myeloid Leukaemia (CML) and during their treatment. Topics mentioned are adherence, choosing the right TKI (Tyrosine Kinase Inhibitor), side effects and individualised treatment for patients.
PP-BOS-GBR-0981. April 2020